A deep learning framework combines convolutional and bidirectional recurrent networks to improve protein function prediction from genomic sequences. By automating feature extraction and capturing long ...
Objectives Understanding the molecular changes in the preclinical synovium is crucial for identifying factors that drive ...
Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.
While a majority of the therapies currently in development are life-long treatments, Genespire is taking a different approach ...
Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...
Cell-free DNA (cfDNA) analysis is transforming precision medicine, offering a non-invasive window into the body, particularly in the context of cancer. This journal collection, hosted by npj Precision ...
New genetic evidence reveals unexpected killers behind one of history’s deadliest military disasters.
Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 years (19 months) for placebo (HR=0.23; p=0.008)7-year ...
Despite decades of research, HIV-1 continues to infect millions annually, underscoring the urgent need for a safe and effective vaccine to curb the ongoing global pandemic. Among the many strategies ...
Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check ...
Under the agreement, Bionova will serve as the preferred manufacturing partner for Syenex’s best-in-class delivery platforms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback